Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Oncology Reviews
|
June 10, 2024
Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology
Ofer Rotem, Karyn Revital Geiger, Ekaterina Hanovich, et al.
JTO Clinical and Research Reports
|
July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer
Daniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
Cancer Immunology, Immunotherapy : CII
|
June 23, 2026
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC)
Elizabeth Dudnik, Hovav Nechushtan, Ofer Rotem, et al.
Oncology
|
July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Oded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Asia-Pacific Journal of Clinical Oncology
|
August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer
Oded Icht, Liran Domachevsky, David Groshar, et al.
Respiration; International Review of Thoracic Diseases
|
November 13, 2018
Increased Risk for Cancer in Young Patients with Severe Obstructive Sleep Apnea
Ronen Brenner, Shaye Kivity, Marina Peker, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study
Itamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Clinical Lung Cancer
|
January 17, 2022
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50
Liran Holtzman, Mor Moskovitz, Damien Urban, et al.
Journal of Neuro-Oncology
|
February 7, 2024
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment
Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 19, 2021
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht, Naama Darzi, Shai Shimony, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Oncology Reviews
|
June 10, 2024
Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology
Ofer Rotem, Karyn Revital Geiger, Ekaterina Hanovich, et al.
JTO Clinical and Research Reports
|
July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer
Daniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
Cancer Immunology, Immunotherapy : CII
|
June 23, 2026
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC)
Elizabeth Dudnik, Hovav Nechushtan, Ofer Rotem, et al.
Oncology
|
July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Oded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Asia-Pacific Journal of Clinical Oncology
|
August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer
Oded Icht, Liran Domachevsky, David Groshar, et al.
Respiration; International Review of Thoracic Diseases
|
November 13, 2018
Increased Risk for Cancer in Young Patients with Severe Obstructive Sleep Apnea
Ronen Brenner, Shaye Kivity, Marina Peker, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study
Itamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Clinical Lung Cancer
|
January 17, 2022
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50
Liran Holtzman, Mor Moskovitz, Damien Urban, et al.
Journal of Neuro-Oncology
|
February 7, 2024
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment
Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 19, 2021
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht, Naama Darzi, Shai Shimony, et al.
Page
of 3